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Background: The degrees to which residual symptoms in major depressive disorder (MDD) adversely affect patient
functioning is not known. This post-hoc analysis explored the association between different residual symptoms and
patient functioning.
Methods: Patients with MDD who responded (≥50% on the 17-item Hamilton Rating Scale for Depression;
HAMD-17) after 3 months of treatment (624/930) were included. Residual core mood-symptoms (HAMD-17 core
symptom subscale ≥1), residual insomnia-symptoms (HAMD-17 sleep subscale ≥1), residual anxiety-symptoms
(HAMD-17-anxiety subscale ≥1), residual somatic-symptoms (HAMD-17 Item 13 ≥1), pain (Visual Analogue Scale
≥30), and functioning were assessed after 3 months treatment. A stepwise logistic regression model with normal
functioning (Social and Occupational Functioning Assessment Scale ≥80) as the dependent variable was used.
Results: After 3 months, 59.5% of patients (371/624) achieved normal functioning and 66.0% (412/624) were in
remission. Residual symptom prevalence was: core mood symptoms 72%; insomnia 63%; anxiety 78%; and somatic
symptoms 41%. Pain reported in 18%. Factors associated with normal functioning were absence of core mood
symptoms (odds ratio [OR] 8.7; 95% confidence interval [CI], 4.6–16.7), absence of insomnia symptoms (OR 1.8; 95%
CI, 1.2–2.7), episode length (4–24 weeks vs. ≥24 weeks [OR 2.0; 95% CI, 1.1–3.6]) and better baseline functioning (OR
1.0; 95% CI, 1.0–1.1). A significant interaction between residual anxiety symptoms and pain was found (p = 0.0080).
Conclusions: Different residual symptoms are associated to different degrees with patient functioning. To achieve
normal functioning, specific residual symptoms domains might be targeted for treatment.
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Residual symptoms of depression cause significant
functional impairment [1,2]. This has been reported in
patients who respond but are not remitters, partial
remitters [1,2], and even in remitters (typically defined
as a score of ≤7 on the 17-item Hamilton Depression
Rating scale [HAMD-17]) with residual symptoms [2].
Residual symptoms are also associated with persistent
functional impairment [1]. However, little is known* Correspondence: romera_irene@lilly.com
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reproduction in any medium, provided the orabout the role of specific residual symptom domains,
such as core symptoms, symptoms of anxiety, somatic
symptoms, and non-painful symptoms.
Most research in patients with residual symptoms has
focused on the relationship between residual symptoms
and depressive relapse. Several studies have shown an
increased risk of relapse [3,4] and rapid relapse [5] in
patients with residual symptoms after response without
remission. A posthoc analysis from the Sequenced
Treatment Alternatives to Relieve Depression [6] study
showed that a greater number of residual symptom
domains were associated with a higher probability of
relapse in full symptomatic remitters. Although a few
studies have evaluated the impact of residual symptomsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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published studies have examined the specific role of each
residual symptom domain on functional impairment.
This is definitely an area worthy of investigation, since
the aim of treating depression is not only to achieve
clinical remission, but also to return the patient to previ-
ous levels of functioning [9]. Knowledge of which re-
sidual symptom domains are associated with significant
functional impairment and, to what degree would assist
physicians in the implementation of specific strategies
and treatments to increase the chances of achieving
normal or previous levels of functioning.
The aim of this posthoc investigation was to assess
the association of specific residual symptoms (core
mood, insomnia, anxiety, somatic, and pain) with
patient functioning in a large group of patients with an
episode of major depressive disorder (MDD) who
responded after 3 months of acute antidepressant
treatment in routine clinical practice. Our hypothesis
was that the strength of the association between
residual symptoms and functioning would differ
depending on the type of residual symptom.
Methods
This study is a post-hoc analysis done on a group of
MDD patients who responded (improvement of ≥50%
on the HAMD-17) after 3 months of acute treatment
(n = 624). The analysis of the association between
residual symptoms and functioning was done at three
months of acute treatment. The source of data was
based on a 1-year prospective observational study of a
cohort of 930 outpatients with an index MDD episode
[10]. As a non-interventional study, the patients were
treated according to everyday clinical routine. The
protocol was approved by the ethical review board of
the Hospital Puerta de Hierro in Madrid, Spain, and all
patients provided written informed consent before
their inclusion in the study.
Participants
As described in detail elsewhere [10], adult outpatients
with nonpsychotic MDD, single or recurrent episode,
according to DSM-IV-TRW [11] were included. Patients
had a baseline total score of ≥15 on the HAMD-17)
[12] and at least a moderate (≥4) baseline score on the
Clinical Global Impression-Severity (CGI-S) scale [13].
Patients suffering from Axis I main psychiatric
disorder, dementia, Alzheimer’s disease, organic brain
syndrome, or cognitive impairment were excluded
from the study.
Patients from this study who responded (improve-
ment of ≥50% on the HAMD-17) after 3 months of
acute antidepressant treatment were included in the
present analysis.Measures and definitions
The HAMD-17 was used to assess the severity of
depression and its improvement. Remission was
defined as a HAMD-17 score of ≤7 and a response as
an improvement of 50% or more from the baseline
score. Functioning was measured using the Social and
Occupational Functioning Assessment Scale (SOFAS)
[14], a 100-point single-item scale used to indicate the
individual’s level of social and occupational functioning
across a continuum ranging from a state of optimum
functioning to a state of important functional impairment.
It measures only the level of social and occupational
functioning without taking symptoms into account.
Thus, a value of 1 represents the hypothetically most
impaired individual and 100 the hypothetically healthiest
individual. It is completed by a clinician using information
from any clinical source. The two highest ranges on the
SOFAS, 81–90 and 91–100, describe individuals who not
only are without significant psychopathology, but who also
exhibit many traits often considered to be components of
positive mental health. A SOFAS score ≥80 was used to
define normal levels of functioning [15]. The baseline and
3-month follow-up visits were included in this analysis.
Based on Dombrovski [16], we defined the presence
of residual core mood symptoms as a score of 1 or
more on the HAMD-17 core symptom subscale
(depressed mood [Item 1], guilt [Item 2], suicide [Item 3],
and anergia/anhedonia [Item 7]). The presence of residual
insomnia symptoms was defined as a score of 1 or more
on the HAMD-17 sleep subscale insomnia items (early
[Item 4], middle [Item 5], and late [Item 6]). The presence
of residual anxiety symptoms was defined as a score of
1 or more on the HAMD-17 anxiety subscale (agitation
[Item 9], psychic anxiety [Item 10], somatic anxiety
[Item 11], and hypochondriasis [Item 15]), and of residual
somatic symptoms as a score of 1 or more for item 13
of the HAMD-17.
The Visual Analog Scale (VAS) for Pain was used to
assess pain [17], defining the presence of pain as a
VAS-overall pain ≥30 mm, which includes patients
with at least moderate pain, and had been previously
used for the identification of clinically significant pain
[18]. The visual analog scale for pain is an instrument
widely used in research studies to measure the level of
pain. Its simplicity, reliability, and validity, make the
VAS the optimal tool for describing pain [19,20]. Pain
was measured by the VAS- overall pain, where the
patient scores on a 100 point scale the level of overall
pain in the last week.
Analysis
Demographic and clinical data at baseline were described
by means of percentages (qualitative variables) or mean ±
standard deviation (quantitative variables).
Table 1 Baseline demographic and clinical characteristics
Characteristics N = 624











Basic school education 252 (40.4)
High school/higher education 316 (50.6)
Employment status, n (%)
Active 264 (42.3)
Not working (unemployed or sick leave) 148 (23.7)
Other2 212 (34.0)
Patients with medical comorbidity, n (%) 339 (54.3)
Family psychiatric history, n (%) 221 (35.4)
Number of previous episodes, mean (SD) 2.6 (2.5)
Patients with 1st episode, n (%) 280 (44.9)
Age at first episode of depression, mean (SD) 40.5 (14.0)
Current depressive episode:
Length, mean weeks (SD) 13.9 (23.5)
Chronicity ≥2 years, n (%) 38 (6.1)
HAMD-17 total score, mean (SD) 24.6 (5.7)
Residual symptoms, mean (SD)
Core mood3 8.7 (2.3)
Romera et al. BMC Psychiatry 2013, 13:51 Page 3 of 7
http://www.biomedcentral.com/1471-244X/13/51A stepwise logistic regression model was developed to
evaluate the association between the residual symptom
domains and patient functioning, with a normal level of
functioning after 3 months of antidepressant treatment
(SOFAS total score ≥80) as the dependent variable, and
the following factors as the independent variables in the
initial model: Age as a continuous variable, gender,
marital status, working status, education status, baseline
functioning (SOFAS score), baseline depression severity
(HAMD-17), presence of previous episodes of depres-
sion, medical co-morbidities, length of current episode,
residual symptoms at 3 months (core mood symptoms,
insomnia symptoms, anxiety symptoms, somatic symp-
toms), and pain at 3 months. All the independent variables
were included in a full model and then removed stepwise
by backward selection (threshold for the p-value = 0.05).
Interactions between variables were tested at 3 months
(likelihood ratio). Only patients with complete informa-
tion on the variables previously described were included
in the model (n = 600). The reduced model was reported
in terms of odds ratios (OR) and their 95% confidence
intervals (CI); the fit of the final model was assessed using
the Hosmer-Lemeshow goodness-of-fit test [21].
Receiver operating characteristics curves were plotted to
determine and compare the sensitivity and specificity of
the residual symptom domains and of the pain, as indica-
tors of normal levels of functioning according to the
SOFAS (SOFAS score ≥80) after 3 months of treatment.
Areas under the curve (AUC) using the trapezoidal rule
and their associated asymptotic 95% CIs were calculated.
The AUC varies from 0.5 (no apparent accuracy) to 1.0
(perfect accuracy). SAS 9.2 for Windows (SAS Institute
Inc., USA) was used for the statistical analysis.Insomnia4 3.9 (1.4)
Anxiety5 6.2 (2.2)
Somatic6 1.1 (0.6)
VAS-overall pain, total score (mean) 41.4 (28.2)
Monotherapy, n (%) 550 (88.1)
SSRI 145 (26.4)
SNRI 387 (70.3)
Tricyclic antidepressants 6 (1.1)
Others 12 (2.2)Results
Patient disposition, demographics, and clinical
characteristics
Of the evaluable sample (N = 930), 624 patients responded
to antidepressant treatment and were therefore included in
the present analysis. Table 1 shows the socio-demographic
and clinical characteristics of the study sample of
responders.Combination of antidepressants, n (%) 74 (11.9)
MDD =Major depressive disorder; SSRI = Selective serotonin reuptake inhibitor;
SNRI = Serotonin-norepinephrine reuptake inhibitor; SD = Standard deviation;
VAS = Visual Analog Scale; 1Widowed, separated, divorced and other;
2Student, housekeeping, retired, disabled worker; 3depressed mood [Item 1],
guilt [Item 2], suicide [Item 3], and anergia/anhedonia [Item 7] of the
HAMD-17; 4early [Item 4], middle [Item 5], and late insomnia [Item 6] of the
HAMD-17; 5agitation [Item 9], psychic anxiety [Item 10], somatic anxiety
[Item 11], and hypochondriasis [Item 15] of the HAMD-17; 6item 13 of
the HAMD-17.Residual symptom prevalence
After 3 months of acute antidepressant treatment, the
most frequent residual symptom was anxiety in 78.2% of
patients (95% CI, 74.8–81.4), followed by core mood
symptoms in 72.1% (95% CI, 68.4–75.6), residual insom-
nia in 63.0% (95% CI, 59.1–66.8) and somatic symptoms
in 41.3% (95% CI, 37.4–45.3). Pain was reported in
18.4% (95% CI, 15.5–21.7) of patients (Figure 1A). The
























































Figure 1 A Prevalence of residual symptoms domains and pain. All patients, N = 624. B Prevalence of residual symptoms domains and pain,
based on remission (HAMD-17 ≤7) N = 412, or non-remission (HAMD-17 >7) N = 212.
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patients were in remission (HAMD-17 ≤7). Figure 1B
shows the prevalence of residual symptoms by remission
status at 3 months. About 90% of remitters (88.3%; 95%
CI, 84.8–91.3) had residual symptoms from at least one of
the domains studied.Table 2 Residual symptoms, pain and HAMD-17 mean
scores after 3 months of acute treatment, N = 624
Residual symptom Mean (SD)





HAMD-17 total score 6.0 (3.8)
SD = Standard deviation.Residual symptoms and patient functioning
More than half of the patients (59.4%, 371/624) had a
normal level of functioning. Factors associated with nor-
mal functioning were absence of core mood symptoms
(OR 8.7; 95% CI, 4.6–16.7), absence of insomnia symp-
toms (OR 1.8; 95% CI, 1.2–2.7), shorter episode length
(4–24 weeks vs. ≥24 weeks [OR 2.0; 95% CI, 1.1–3.6])
and better baseline functioning (OR 1.0; 95% CI, 1.0–1.1).
A significant interaction was found between residual anx-
iety symptoms and pain (p = 0.0080). The absence of pain
increased the chance of normal functioning in either the
absence (OR 21.7; 95% CI, 3.5–132.5) or presence of
residual anxiety (OR 1.7; 95% CI, 1.0–2.8). However, the
absence of residual anxiety was found to increase the
chance of normal functioning only if pain was not present
(OR 5.2; 95% CI, 2.4.–11.3) (Table 3). Demographic
variables, physical co-morbidities, baseline depression
severity, previous depression episodes and residual
somatic symptoms were not significantly related to
functioning (Table 3).
Table 3 Association between residual symptoms domains, pain and functioning
Odds Ratio 95% Wald Confidence Limits
Age 0.990 0.975 1.005
Gender (male vs. female) 1.356 0.886 2.076
Academic degree (high vs. other) 1.580 0.949 2.629
Baseline functioning level (SOFAS) 1.049 1.031 1.067
Episode length (4–24 weeks vs. ≥ 24 weeks) 2.008 1.127 3.579
Episode lenght (≤4 weeks vs. ≥24 weeks) 2.138 1.145 3.992
Absence of residual core mood symptoms 8.728 4.553 16.730
Absence of residual insomnia symptoms 1.796 1.175 2.744
Absence of residual anxiety symptoms and absence of pain 5.257 2.445 11.300
Absence of residual anxiety symptoms and presence of pain 0.412 0.073 2.341
Absence of pain and absence of residual anxiety symptoms 21.669 3.544 132.498
Absence of pain and presence of residual anxiety symptoms 1.700 1.025 2.819
Logistic regression model.
SOFAS = Social and Occupational Functioning Assessment Scale;
Dependent variable: normal level of functioning (SOFAS total score ≥80) after 3 months of antidepressant treatment.
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0.84 (95% CI, 0.80–0.87). Lower AUCs were found for
the other residual symptom domains and pain: anxiety
0.75 (95% CI, 0.71–0.78); pain 0.73 (95% CI, 0.69–0.77);
insomnia 0.65 (95% CI, 0.60–0.69); and residual somatic
symptoms 0.62 (95% CI, 0.58–0.66).
Discussion
This study evaluated the relationship between patient
functioning and specific residual symptom domains
(core mood, insomnia, anxiety, somatic symptoms) and
pain symptoms in a large group of patients with MDD
who responded after receiving acute treatment. Anxiety
was the most prevalent residual symptom, followed by
core mood symptoms. The strength of the association
between the residual symptom domains studied and
patient functioning differed depending on the type of
symptoms. A more marked association was found for
residual core mood symptoms. Residual insomnia was
less strongly related to patient functioning, and residual
somatic symptoms were not associated.
To our knowledge, this is the first study to investigate
the role of specific residual symptoms on patient func-
tioning in MDD. Most publications about residual
symptoms in MDD focus on their description and on
their relationship to relapse and recurrence of depres-
sion [6,22-27]. More recent publications have evaluated
their relationship to time to remission [6,28]. Few
studies have specifically investigated the relationship
between residual symptoms and functional impair-
ment, but instead have focused on the overall impact
of these symptoms on functioning without a separate
analysis of the type of residual symptom [1,8,29].
As reported previously, residual symptoms are very
common after acute treatment, even in remitters[6,22,23]. In the present investigation, we found that al-
most 90% of remitters had at least one residual symp-
tom domain of mild intensity. This is similar to figures
reported by Nierenberg et al. [6] and Ioveno et al. [22].
Similar to other studies, the most common residual
symptom domain in our patients was anxiety [6,26].
Other studies have reported residual insomnia [23] and
sleep disturbances [6,22] to be the most common
residual symptoms domains. These differences may be
due to the use of different scales and definitions. Devel-
opment of a consensus on the definition and measure-
ment of residual symptoms would be desirable to enable
results between studies to be compared, thus improving
understanding.
Interestingly, we found the strongest association
between patient functioning and residual core mood
symptoms, and we also found a significant interaction
with pain and anxiety. The absence of pain increased
the chances of normal functioning, regardless of the
presence of residual anxiety. However, the absence of
residual anxiety increased the chances of normal func-
tioning only if pain was not present. Of note, we found
residual insomnia significantly less strongly related to
patient functioning than residual core mood symptoms.
In addition, no association was found for residual som-
atic symptoms. It is remarkable that baseline depression
severity and previous depression episodes were not sig-
nificantly related to functional impairment. This further
supports the previous finding that residual symptoms
are more important than previous episodes of depres-
sion in the prognosis of the patient [5].
The different degree of association of each residual
symptom with patient functioning might have prog-
nostic implications and requires further investigation.
In line with this, several recent studies tried to identify
Romera et al. BMC Psychiatry 2013, 13:51 Page 6 of 7
http://www.biomedcentral.com/1471-244X/13/51which specific residual symptoms are predictive of
relapse or recurrence [16,26,30,31]. Residual anxiety
symptoms were found to be predictive of relapse
[26,30,31]. The picture for residual insomnia was less
clear, with both positive [16,30] and negative associa-
tions reported [6]. Although preliminary, these find-
ings suggest that some residual symptoms present a
greater risk for relapse than others.
This study has the following limitations: The primary
study from which our data were drawn was not designed
to assess residual symptoms, and our results are based
on a post-hoc analysis. Our analysis has inherent limita-
tions of post-hoc analysis; measures were those used in
the source study. Antidepressant history, before base-
line, was not collected, therefore percentage of naïve
patients and already treated patients are unknown. This
analysis has included a selected population of patients
with MDD; patients who had a response to acute anti-
depressant treatment. This may limit the generalizability
of the results to other types of patients not included in
this analysis. Our research focused on selected residual
symptoms domains and did not include domains such
as fatigue or other symptoms not included in the
HAMD-17. We also cannot rule out the possibility that
a small proportion of the symptoms reported might
have been treatment-emergent and not residual.
Conclusions
In summary, our results contribute to a better under-
standing of the role of specific residual symptoms
domains on functional impairment in depression. We
found that different residual symptoms have different
degrees of association with patient functioning. This
indicates that specific residual symptoms domains may
be targets for intervention if normal functioning is the
treatment objective.
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